Lightwave's system combines multiple channels on demand to give surgeons a clear view of the margins between cancer and healthy tissue
Source: International Society for Fluorescence Guided Surgery
source: Avelas Biosciences
source: OnTarget Labs
Optical imaging is the next paradigm for safe and accurate imaging of cancer at its earliest stage possible. Lightwave Diagnostics has pioneered the most sensitive detector system with eight or more concurrent imaging channels and the broadest wavelength spectrum in the industry.
Lightwave's optical sensor system has reached a level of sensitivity where it can measure extremely low energy light waves in the ultraviolet, visible and infrared spectrum to detect and diﬀerentiate cancer cells and tumors from normal cells and tissue without the harmful ionizing radiation from X-Rays nor the radioactive emissions from PET scanning that damage healthy cells with their high energy levels.
Lightwave Diagnostics has advanced the sensor technology and software algorithms to make optical imaging more sensitive and specific for cancer detection. The optical imaging modality can now be applied to a) all types of cancer screening, b) detecting metastasis and single cell invasion to surrounding tissue, c) image-guided surgery to detect and assure complete resection of cancer cells, and d) follow-up screenings to monitor the efficacy of therapies and the state of remission.
Optical imaging has the potential to transform how we detect and treat cancer with safe, low cost, regular screening. Early detection can change a diagnosis of cancer from a life-threatening disease to a short-term treatment with full recovery.
Portable and low-cost optical sensors will make it possible to provide cancer screening services much more broadly, particularly for underserved and disadvantaged populations, and reducing the burden of cancer on all of society.
The USFDA has already issued a letter designating Lightwave Diagnostics’ proposed clinical trial as a nonsignificant risk (NSR) device study, which allows the technology to proceed to clinical trials without the need for an Investigational Device Exemption. A breast cancer screening clinical trial is in the planning stage with a leading medical center in Florida.
The optical sensor technology is small, portable and customizable for different settings and applications. Different screening procedures for different types of cancers will call for different sensor configurations and functions: eight (8) sensors for surgical applications, thirty-two (32) sensors for breast cancer imaging, etc.. The systems can also be adapted to work in combination with other imaging modalities like ultrasound and MRI to impove the diagnostic sensitivity and specificity of the combined imaging results.
To eliminate late stage cancer through early detection for as many people in the world as we can. To develop and deploy optical sensor technology and advanced analytical software for cancer detection and imaging.
Our team includes:
Member of NVIDIA Inception Program
Member of NVIDIA Developer Program
Member of IBM PartnerWorld
Foundation for Early Detection of Disease
Mr. Stetson is the Founder of Lightwave Diagnostics, LLC, and driven by his personal motivation to beat cancer with his professional expertise in digital imaging and data analytics. In June of 2022 Mr. Stetson completed an 18-month Cooperative R&D Agreement (CRADA) with the National Institute of Biomedical Imaging and Bioengineering at NI
Mr. Stetson is the Founder of Lightwave Diagnostics, LLC, and driven by his personal motivation to beat cancer with his professional expertise in digital imaging and data analytics. In June of 2022 Mr. Stetson completed an 18-month Cooperative R&D Agreement (CRADA) with the National Institute of Biomedical Imaging and Bioengineering at NIH involving his imaging technology. His experience in the fields of automated image analysis and artificial intelligence began in the 1980's. Over the years, NASA, DoD and several other federal agencies, foreign governments and private corporations have relied upon Mr. Stetson's expertise to develop a variety of imaging solutions. Now, he is applying his knowledge to beating cancer!
Leading up to his role at Lightwave Diagnostics, Mr. Jackson has been the Managing Director of ETEC Consulting Group, a consultancy specializing in Quality and Risk Management Systems, and engineering and business process improvement for Fortune 500 clients worldwide. His knowledge of QM and RM protocols are essential to regulatory approval of Lightwave Diagnostics' medical solutions.
Dr. Kraft earned his M.D. from Georgetown University Medical School. He then spent two decades serving as Chairman and Vice- Chairman of two community hospital departments. Dr. Kraft has had a dual career, medicine and highly scalable software. He has also been a CEO and a C-level executive at multiple software companies and filed numerou
Dr. Kraft earned his M.D. from Georgetown University Medical School. He then spent two decades serving as Chairman and Vice- Chairman of two community hospital departments. Dr. Kraft has had a dual career, medicine and highly scalable software. He has also been a CEO and a C-level executive at multiple software companies and filed numerous patents. Dr. Kraft guides the team with his knowledge of the medical field and software development.
Mr Riker has over two decades experience in business strategy, as former CEO at Capgemini Telecom, Media, Networks, and currently as Senior Professor of the Blue Ocean Academy and Managing Director of the Blue Ocean Strategy Initiative Centre. Mr Riker has worked to shape and execute high-growth strategies across numerous industries, geo
Mr Riker has over two decades experience in business strategy, as former CEO at Capgemini Telecom, Media, Networks, and currently as Senior Professor of the Blue Ocean Academy and Managing Director of the Blue Ocean Strategy Initiative Centre. Mr Riker has worked to shape and execute high-growth strategies across numerous industries, geographies and product markets. Mr. Riker serves as the Director of Business Strategy to optimize the market value of Lightwave's imaging solutions.
Nathan Hagen graduated with a PhD degree in Optical Sciences at the University of Arizona in 2007, studying snapshot imaging spectrometry and spectropolarimetry. After working as a postdoc at Duke University and Rice University, in 2011 he joined Rebellion Photonics, in an effort to develop snapshot imaging spectrometers as commercial products. By 2016 Rebellion Photonics had become a successful company and financially independent, and Dr. Hagen moved to join the newly-formed Optical Engineering department at Utsunomiya University in Japan. He has produced 14 patents and published over 40 peer-reviewed journal articles.
“The greatest advances in cancer research will be obtained — and more lives saved — by focusing translational research on early detection.”
"Earlier diagnosis is the most promising approach to improve long-term survival of patients with cancer." Professor Rebecca Fitzgerald
"The early detection and interception of cancer will be one of the main ways in which we will beat the disease in the future. Not only does it provide routes to more effective treatment, it also provides health systems around the world a way in which to grapple with the mounting costs of care in complex diseases such as cancer."
Dr Iain Foulkes, Executive Director Research & Innovation, CRUK
The new knowledge that has revolutionized treatment, has done little to help catch cancer early and ideally, prevent it.
Even as treatment options have dramatically improved, with once-a-day pills that target the specific biology of each patient’s disease, early detection of cancer has been frozen in time. Today, we still use the same screening tools that we’ve deployed for decades. Mammograms and PSA tests for prostate cancer are the best we have today, but they’re woefully inadequate. They miss some cancers while triggering many unnecessary biopsies and treatments.
We know cancer is an easier foe when caught early. It is cheaper to treat. And patients live longer and suffer less when it is detected early. Indeed, targeted therapy and early detection will prove to be inextricably linked. Early stage cancers are easier to treat because they harbor fewer mutations and molecular defects.
Earlier diagnosis of cancer offers the greatest potential for transformational improvements in patient outcomes.
The chances of survival are increased significantly for almost all patient groups if the disease can be diagnosed and treated at an early stage. For example, a patient diagnosed with stage 1 lung cancer has over 70% chance of survival beyond one year. This drops to less than 15% if diagnosed at stage 4.
Support early cancer detection through tax deductible contributions